Can CymaBay Therapeutics (CBAY) Stock Bounce Back from Recent Selloff?

 

CymaBay Therapeutics Inc (CBAY) stock is down more than -50% over the past week. CBAY stock has fallen -50.73% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives CBAY stock an overall score of 27 out of a possible 100.

That score is primarily influenced by a short-term technical score of 0. CBAY’s score also includes a long-term technical score of 1. The fundamental score for CBAY is 80. In addition to the average rating from Wall Street analysts, CBAY stock has a mean target price of $21.00. This means analysts expect the stock to add 244.26% over the next 12 months.

Click Here to get the full Stock Score Report on CymaBay Therapeutics Inc (CBAY).

What’s Happening with CBAY Stock Today

CymaBay Therapeutics Inc (CBAY) stock has gained 0.74% while the S&P 500 has fallen -0.32% as of 12:22 PM on Wednesday, Jun 12. CBAY is higher by $0.04 from the previous closing price of $6.05 on volume of 3,688,572 shares. Over the past year the S&P 500 is up 3.39% while CBAY has fallen -50.73%. CBAY lost -$1.31 per share in the over the last 12 months.

Symbols: CBAY

You May Also Like